JK-273

CAS No. 187723-38-2

JK-273( JK273 )

Catalog No. M12911 CAS No. 187723-38-2

A small molecule inhibitor of α4 integrin-dependent cell migration that functions by interacting with γ-parvin.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    JK-273
  • Note
    Research use only, not for human use.
  • Brief Description
    A small molecule inhibitor of α4 integrin-dependent cell migration that functions by interacting with γ-parvin.
  • Description
    A small molecule inhibitor of α4 integrin-dependent cell migration (IC50=0.5 uM, on the motility of Jurkat T cells) that functions by interacting with γ-parvin; inhibits α4 integrin signaling, shows a selective cytotoxic effect against HCI-H460 NSCLC cells with IC50 of 0.98 uM, less sensitivity to fibroblasts (30-fold selectivity), causes cell cycle arrest at S phase and induces apoptosis.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    JK273
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    Integrin
  • Recptor
    Integrin
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    187723-38-2
  • Formula Weight
    335.795
  • Molecular Formula
    C18H14ClN5
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    6-(4-aminophenyl)-N-(3-chlorophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Lee J, et al. Bioorg Med Chem. 2009 Feb 1;17(3):977-80. 2. Lu TN, et al. Biochem Biophys Res Commun. 2017 Sep 16;491(2):355-360.
molnova catalog
related products
  • MK-0429

    MK-0429 is a potent, selective, orally-active nonpeptide αvβ3 integrin inhibitor with IC50 of 0.08 nM in SPAV3 assay.

  • Cilengitide

    Cilengitide is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.

  • AJM300

    AJM300 (AJM 300, AJM-300) is a novel potent, selective, oraaly available alpha 4 integrin antagonist fortreatment of active ulcerative colitis.